Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of a novel combination
antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in
treatment-naive patients infected with R5-tropic HIV-1. The hypothesis is that in
treatment-naive subjects infected with R5-tropic HIV-1, combination antiretroviral therapy
with maraviroc plus darunavir/ritonavir is well tolerated and efficacious.